Addiction

The soon-to-be marketed therapy Dsuvia has shown enough benefit, tolerability, and safety to aid an at-need patient population in a controlled setting.

Increased opioid prescribing correlated with marketing opioid products to physicians, which subsequently correlated with an increase in mortality from overdoses.

A retrospective study showed which patients with substance use disorder may have less successful antiepileptic drug treatment.

The rate of youths using flavored tobacco products increased by nearly 7% from 2016 to 2017.

A series of recently presented studies support the notion of treating hepatitis C in patients already on opioid substitution therapy.

The Second Chance app from University of Washington investigators is seeking FDA consideration in the near future.

The FDA has approved 2 new dosages of the pain reliever that combines benzhydrocodone and acetaminophen.

New research finds patients face a higher risk of pneumonia if they are taking opioids. The danger is even more pronounced for patients living with HIV.

MD Magazine's most popular stories this year ranged from new clinical insights, to physician-submitted columns, to perspectives on burnout in the workplace.

A step-by-step look into how Arctic Surgery Group treats postoperative patients.

How an Alaska-based surgical group responded to the opioid epidemic with a multi-step strategy of pain management care.

Investigators also found that opiate agonist therapy could have a positive effect in limiting reinfection rates after patients achieve SVR.

In a clinical trial, the reSET-O app increased retention in an outpatient opioid use disorder treatment program.

How the opioid epidemic and high drug prices have brought the hepatitis C burden onto a younger population in 2018.

Investigators found that among adolescents that began as never users, e-cigarette users were more likely to become experimental, infrequent or frequent combustible cigarette users.

Young people who inject drugs tell why they do not—or cannot— receive treatment for hepatitis C virus infection.

A new meta-analysis finds people who were recently incarcerated face significantly higher risks of contracting hepatitis C and HIV infection.

Investigators have found an association between opioid use and cardiovascular mortality.

There are 3 FDA-approved medications available to treat opioid use disorder, and different treatment approaches that can aid patients on the road to recovery.

Added stigma further burdens the treatment of patients with opioid use disorder, but the medical community can do something about it.

Lindsey Jennings, MD, MPH, and Carolyn Bogdon, MSN, FNP-BC, of Medical University of South Carolina discuss the challenges facing health care providers who are on the front line of battling the opioid epidemic.

The most reliable practice for helping a patient quit is comprehensive, and catered to their medical, physical, and financial goals.

Coverage of the post-surgery pain management therapy's strength has overlooked its clinical setting use and potential need.

People who are addicted to drugs face a higher risk of contracting HCV. Yet, a new study suggests the majority teens who are addicted to opioids don’t get screened for the virus.

Active-duty military personnel report a deadly opioid overdose rate just one-fourth of the general population. What does the military do with its patient registries that could be repeatable in public health?

Research demonstrates that medication-assisted treatment for opioid addiction works, yet few have adopted it.

A meta-analysis shows the experimental therapy has favorable benefits for certain aspects of pain, as well as preferrable avenues of administration.

Evidence from a number of countries suggests that America’s expansion of opioid addiction treatment programs will pay dividends in curbing rates of HIV transmission among people who inject drugs.

After 10 days of transcranial magnetic stimulation, patients reported significant decreases in withdrawal symptoms like craving, quality of sleep, and mood status.

The sublingual film therapy has been approved under a 16 mg/ 4 mg dosage strength for the maintenance treatment of opioid dependence, adding to therapy options which include both brand name and generic versions.